Recombinant factor Vlla therapy in a patient on long term anticoagulant treatment with a bleeding and acute subdural hematoma by Nataša Kovač et al.
25www.signavitae.com
Recombinant factor Vlla 
therapy in a patient on 
long term anticoagulant 
treatment with a bleeding 
and acute subdural 
hematoma
ABSTRACT
In this paper we report on the successful correction of a coagulopathy with activated recombinant factor seven (rFVIIa) 
therapy which enabled surgical removal of a life threatening subdural hematoma. The severe coagulopathy developed due 
to long term warfarin therapy, which followed heart valvular reconstruction and replacement. The coagulopathy failed to 
improve following fresh frozen plasma and vitamin K therapy.  Activated recombinant factor VII therapy became the treatment 
of choice, which enabled the life saving surgical removal of the subdural hematoma.
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Introduction
Recombinant activated coagulation 
factor VII (rVIIa) has been developed 
as a suitable way for the treatment of 
spontaneous and surgical bleeding in 
patients with congenital and acquired 
hemophilia with antibodies (inhibitors) 
against factor VIII (FVIII) and factor 
IX (FIX) (1). In addition, it is a useful 
hemostatic agent proven effective 
in numerous other diagnostic and 
therapeutic procedures like biopsies 
in liver disease, thrombocytopenia with 
bleeding, total hip replacement, etc.(3, 
9, 10). rFVIIa induces hemostasis at 
the site of injury independent of the 
presence of FVIII and by forming 
complexes with exposed tissue factor 
(TF) (1). It bypasses activation of factor 
VIII and directly activates factor X into Xa 
and IX into IXa. The natural factor seven 
(FVII) is a vitamin K dependent protease 
primarily synthesized by the liver (4). 
Therefore, rFVIIa treatment could 
be effective and clinically protective 
in hemorrhages and coagulopathies 
caused by liver dysfunction (4). The 
long-term anticoagulant, warfarin, 
decreases circulating levels of vitamin 
K-dependent coagulation factors and 
increases the risk of hemorrhagic 
complications. Intracranial bleeding is 
one of the most ominous complications 
of anticoagulant therapy, calling for 
immediate intervention. 
In this paper, rFVIIa therapy is described 
which led to a rapid correction of 
coagulation system abnormalities and 
enabled urgently required, life saving 
surgery.
Case report
A 35-yr-old woman was admitted 
to hospital with nausea, vomiting, 
headache and drowsiness. She was 
hardly communicative with a GCS 12 
and mild left sided weakness. Her 
pupils were reactive and isocoric.  Head 
CT scan revealed a large hemispheral 
subdural hematoma with basal tutorial 
spread. Urgent surgical removal of the 
hematoma was indicated.
The patient was on long term, pro-
phylactic, oral anticoagulant therapy with 
warfarin  (6 mg daily) because of valvular 
heart surgery done 4 years ago. That 
operation had included the implantation 
of a tricuspid valve, commissurotomy 
of the mitral valve, and reconstruction 
of the aortic valve. The primary cause 
of the structural disintegration and 
functional valvular failure had been 
rheumatic fever in childhood. On 
admission, the acute coagulopathy was 
life threatening. The prothrombin time 
(PV) was 3%  (normal value 70-130 %) 
and partial thromboplastin time (PTT) 
was 106 seconds (normal value 26-36 
26 www.signavitae.com
REFERENCES
1. Arkin S, Cooper HA, Huntter JJ, et al: Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patient 
with hemophilia A or B with inhibitors. Haemostasis 28:93-98,1998
2. Abu-Hajir M, Hollowell J, Nagaroje G: Managment of 2 patients with subdural hematoma and coagulopathy with recombinant human 
activated Factor VII . Blood,  98:79b (11 Part 2), 2001 (Abstract)
3. Al Douri M, Shafi T, Al Khudairi D, et al: Effect of the administration of recombinant activated factor VII (rVIIa; NovoSeven  (R) ) in the 
management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagulation and Fibrinolysis 
11 (Suppl 1):S121-S127, 2000
4. Bernstein ED, Jeffers L, Erhardtsen E, et al: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study: 
Gastroenterology 113:1930-1937, 1997
5. Billion S, Le Niger C, Escoffre-Barbe M, et al: The use of recombinant factor VIIa (NovoSeven (R)) in a patient with a factor XI deficiency 
and circulating anticoagulant. Blood Coagulation and Fibrinolysis 12 :551-553, 2001
6. Deveras RAE, Kessler CM: Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized 
ratios (INR) and prothrombin times induced by warfarin. Blood 96 (11 Part 1):  638a, 2000
7. Deveras RA, Kessler CM: Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate. Ann 
Inter Med. 137:884-888, 2002
8. Hender U: Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Semin Hematol 38 (4 Suppl 12):43-47, 2001
9.  Hendriks GDH, Van der Maaten JMAA, De Wolf J, et al: An Effective Treatment of Severe Intractable Bleeding After Valve Repair by One 
Single Dose of Activated Recombinant Factor VII. Anesth analg 93:287-289, 2001
10. Kessler C: Hemorrhagic complication of thrombocytopenia and oral anticoagulant: Is there a role for recombinant activated factor VII ?. 
Intensive Care Med 28 (Suppl 2):S228,  2002 
seconds), thrombin time (TT) was 14 
seconds (normal value 14-21 seconds) 
and fibrinolysis 195, thrombocyte 
count was 153 x 10e9/L. The indicated, 
urgent, pending surgical procedure 
posed a high r isk for excessive 
bleeding. Fresh frozen plasma (FFP) 
1200ml (20ml/kg) and vitamin K 20 mg 
were administered. Correction of the 
coagulation parameters was slow. Three 
hours later, following FFP and vitamin K 
administration, the PV still remained 
too low (34%).  In order to facilitate 
surgery, with a clinically acceptable 
PTT, we administered 1,2 mg of rFVIIa 
intravenously and repeated the same 
dose two hours later in the operating 
theatre (rFVIIa - NovoSeven produced 
by Novo Nordisk A/S, Bagsvaerd, 
Denmark). The coagulation parameters 
improved quickly reaching a PV 124% 
and PTT 33 seconds within this short 
period of time. During the operation 
no excessive bleeding occurred. The 
postoperative recovery was smooth and 
functional status normalized. Control 
CT scans ruled out any postoperative 
bleeding and appropriate intracranial 
structural relations were recorded. At the 
same time, the induced high PV might 
have been a risk factor for a thrombotic 
complication on the artificial heart valve 
surfaces. In order to continue with 
anticoagulant prophylaxis, the patient 
was treated with a continuous heparin 
infusion and gated to an acceptable PTT 
(70-80%). No thrombotic complications 
occurred in the postoperative period. 
Discussion
Warfarin, a widely prescribed oral 
anticoagulant, is used for the prevention 
of primary and secondary venous and 
arterial thromboembolic complications 
(6). In the case of our patient, prolonged 
warfarin therapy was prescribed to 
prevent thrombi formation, chronic 
atrial fibrillation and to maintain the 
mechanical prosthetic heart valves. The 
most common complication of warfarin 
use is adverse bleeding. Such therapy 
caused the acute bleeding and subdural 
hematoma, which the patient presented 
with on admission. Since fresh frozen 
plasma and vitamin K therapy failed 
to achieve safe hemostasis, rFVIIa 
was used to treat the bleeding. This 
procedure turned out to be very 
effective. The coagulation parameters 
improved and normalized promptly. 
The rapid correction made the urgent 
surgical procedure possible.
The administered dose of rVIIa was 
given according to the manufacturer’s 
recommendation taking into account 
the pat ient ’s  body weight .  The 
recommended doses for patients with 
hemophilia and alloantibody inhibitors 
are between 90 mcg/kg to 120mcg/
kg (8). Lower doses 15 mcg/kg to 
20mcg/kg are shown to procure an 
adequate hemostasis in patients with 
other disorders of coagulation (7). 
Our patient promptly reacted to two 
repeated doses of 20 mcg/kg.
rFVIIa was developed as a new 
approach to hemophilia treatment. 
It has been used in various non-
hemophilia patients with a few adverse 
events (2, 3, 9). Several case reports 
and small series have reported rFVIIa 
as effective and safe therapy in patients 
with trauma and abdominal surgery, 
other surgical indications as well as 
for some diagnostic procedures (3, 9, 
10).  Our report indicates that correction 
of warfarin induced coagulopathy in 
neurosurgery may be an additional 
indication for rFVIIa therapy.
Conclusion
In this paper we reported effective 
rFVIIa therapy in warfarin induced 
coagulopathy in neurosurgical patient. 
The fast improvement of hemostasis 
and the control of bleeding enabled 
the life saving neurosurgical operation, 
when effects of vitamin K and fresh 
frozen plasma were of limited value. 
